Results 91 to 100 of about 47,572 (272)

Voriconazole-Induced Diffuse Periostitis

AACE Clinical Case Reports, 2022
Voriconazole treatment has been associated with diffuse periostitis, especially in immunocompromised patients who have had transplants or are on immunosuppressants. Here, we present a case of diffuse periostitis induced by prophylactic low-dose voriconazole for pulmonary aspergillosis.A 66-year-old woman presented with 1 year of progressive, diffuse ...
Simona Stefan, Nadera Altork, Yazan Alzedaneen, Hilary Whitlatch, Kashif M. Munir   +4 more
openaire   +3 more sources

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

Invasive trichosporonosis treated with voriconazole [PDF]

JAAD Case Reports, 2018
Trichosporon is a genus of yeast-like fungi. It is perhaps most widely known as the cause of white piedra, a benign superficial mycosis seen in immunocompetent individuals in tropical and subtropical regions. However, the incidence of invasive trichosporonosis has increased in immunocompromised patients, most notably those with hematologic malignancies.
Garg, Vaibhav, Jones, Elizabeth, Friedman, Ben J., Lee, Jason B., Yang, Sherry   +4 more
openaire   +4 more sources

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis

Frontiers in Pharmacology
Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was associated with the CYP2C19 phenotype. However, the combined effects of CYP2C19
Jing Ling, Xuping Yang, Lulu Dong, Yan Jiang, Sulan Zou, Nan Hu   +5 more
doaj   +1 more source

Voriconazole‐Associated Periostitis: New Insights into Pathophysiology and Management

JBMR Plus, 2022
Voriconazole‐associated periostitis (VAP) is an underrecognized and unpredictable side effect of long‐term voriconazole therapy. We report two cases of VAP occurring in the post‐transplant setting: a 68‐year‐old lung transplant recipient who required ...
Michael J Bennett, Matthew I Balcerek, Edward AD Lewis, Roland LL Zhang, Caroline Bachmeier, Siok Tey, Steven Faux, Laila Girgis, Jerry R Greenfield, Syndia Lazarus   +9 more
doaj   +1 more source

Saliva as a TDM matrix and its application in the model‐informed precision dosing

The Journal of Clinical Pharmacology, EarlyView.
Abstract This study reviews the main points of saliva as a therapeutic drug monitoring (TDM) matrix, its advantages and limitations, the methods of saliva sample collection and testing, the types of drugs in saliva TDM, and the methods of establishing saliva population pharmacokinetic (Pop PK) models, as well as summarizes the experiences and ...
Baohua Xu, Yujie Wen, Jinxia Lu, Maobai Liu, Xin Luo, Wei Huang, Helin Xie, Yu Cheng, Hongqiang Qiu, Xuemei Wu   +9 more
wiley   +1 more source

Voriconazole pharmacogenetics [PDF]

The Lancet, 2021
Nicolas, Pallet, Marie Anne, Loriot
openaire   +2 more sources

Therapeutic Drug Monitoring of Voriconazole [PDF]

Therapeutic Drug Monitoring, 2008
Voriconazole is a triazole antifungal developed for the treatment of life-threatening fungal infections in immunocompromised patients. The drug, which is available for both oral and intravenous administration, has broad-spectrum activity against pathogenic yeasts, dimorphic fungi, and opportunistic molds.
Bruggemann, R.J.M., Donnelly, J.P., Aarnoutse, R.E., Warris, A., Blijlevens, N.M.A., Mouton, J.W., Verweij, P.E., Burger, D.M.   +7 more
openaire   +4 more sources

Pharmacists' views on the implementation of therapeutic drug monitoring in oncology

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background There is increasing interest in the potential benefit of therapeutic drug monitoring (TDM) in oncology. However, uptake in Australian hospitals is limited. Aim This study sought to explore hospital pharmacists' experiences with TDM in oncology, seeking to determine if they could provide insights into barriers and facilitators to its
Jane E. Carland, Bridin Murnion, Thomas Sakellaris, Jana Stojanova   +3 more
wiley   +1 more source

24(S)-Hydroxycholesterol protects the ex vivo rat retina from injury by elevated hydrostatic pressure [PDF]

, 2016
In the central nervous system, 24(S)-hydroxycholesterol (24(S)-HC) is an oxysterol synthesized from cholesterol by cholesterol 24-hydroxylase (CYP46A1) encoded by the cyp46a1 gene.
Ishikawa, Makoto, Izumi, Yukitoshi, Yoshitomi, Takeshi, Zorumski, Charles F   +3 more
core   +3 more sources